How did Phio Pharmaceuticals' cost-cutting measures impact Q4 2024 profitability?

Phio Pharmaceuticals' cost-cutting measures had a significant impact on the company's Q4 2024 profitability, as evidenced by the reported net income of -$1.63 million for the period. 1. **Focus on Core Programs**: Phio Pharmaceuticals has been focusing on its core programs, particularly the development of PH-762, which is a key factor in the company's strategy to reduce costs while maintaining its clinical trial progress. 2. **Efficient Resource Allocation**: By prioritizing its core programs, Phio Pharmaceuticals has been able to allocate resources more efficiently, which is crucial in reducing costs without compromising the development of its lead compound. 3. **Clinical Trial Progress**: The company's progress in its Phase 1b clinical trial for PH-762 has been positive, with the Safety Monitoring Committee endorsing a higher dose for further testing. This progress indicates that the company's cost-cutting measures are not compromising the development of its lead candidate. 4. **Financial Stability**: Phio Pharmaceuticals has maintained a strong liquidity position with a current ratio of 5.65, which suggests robust short-term financial stability. This financial stability is a result of the company's strategic cost-cutting measures and its focus on securing funding only for essential operations and developments. In conclusion, Phio Pharmaceuticals' cost-cutting measures have had a significant impact on its Q4 2024 profitability, but the company's strategic focus on core programs, efficient resource allocation, and clinical trial progress suggest that these measures are contributing to the company's overall financial stability and long-term viability.